Recurrent Breast Cancer Completed Phase 1 / 2 Trials for Cixutumumab (DB12250)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00699491Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerTreatment